Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Indivior Pharmaceuticals (INDV) Cash & Current Investments (2021 - 2025)

Historic Cash & Current Investments for Indivior Pharmaceuticals (INDV) over the last 5 years, with Q3 2025 value amounting to $445.0 million.

  • Indivior Pharmaceuticals' Cash & Current Investments rose 2861.27% to $445.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $445.0 million, marking a year-over-year increase of 2861.27%. This contributed to the annual value of $320.0 million for FY2024, which is 5622.44% down from last year.
  • Per Indivior Pharmaceuticals' latest filing, its Cash & Current Investments stood at $445.0 million for Q3 2025, which was up 2861.27% from $510.0 million recorded in Q2 2025.
  • In the past 5 years, Indivior Pharmaceuticals' Cash & Current Investments ranged from a high of $1.1 billion in Q4 2021 and a low of $320.0 million during Q4 2024
  • For the 5-year period, Indivior Pharmaceuticals' Cash & Current Investments averaged around $659.1 million, with its median value being $689.0 million (2023).
  • Its Cash & Current Investments has fluctuated over the past 5 years, first plummeted by 5622.44% in 2024, then surged by 3456.46% in 2025.
  • Indivior Pharmaceuticals' Cash & Current Investments (Quarter) stood at $1.1 billion in 2021, then fell by 18.97% to $893.0 million in 2022, then dropped by 18.14% to $731.0 million in 2023, then plummeted by 56.22% to $320.0 million in 2024, then surged by 39.06% to $445.0 million in 2025.
  • Its Cash & Current Investments was $445.0 million in Q3 2025, compared to $510.0 million in Q2 2025 and $373.0 million in Q1 2025.